Alan Bruce Montgomery
CIK 1313936 · SVP, Respiratory Therapeutics · last filed 2026-07-08
Alan Bruce Montgomery is a SVP, Respiratory Therapeutics who has filed 37 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for XNCR, was dated Jul 8, 2026. Across all open-market trades the lifetime net is −$519.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $905.5K across reported positions. 23 SEC filings were submitted jointly with Xencor Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
XNCR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
465 N. HALSTEAD ST. SUITE 200
PASADENA, CA 91107
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XNCR | Director | 25,849 | $35.03 | $905.5K | -$519.0K | 17 | 2026-07-08 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | — | — | — | $0 | 5 | 2019-05-28 |
| ZYMOGENETICS INC (ZGEN) Delisted | Director | — | $12.01 | — | $0 | 1 | 2010-03-11 |
| GILD | SVP, Respiratory Therapeutics | — | $174.48 | — | $0 | 1 | 2007-01-24 |
Recent Filings
37 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-08 | XNCR | Grant (A) | +10,302 | $0 | EDGAR |
| 2026-06-17 | XNCR | Sell (S) | −5,064 | -$62.3K | EDGAR |
| 2026-06-15 | XNCR | Notice (144) | −5,064 | -$62.3K | EDGAR |
| 2025-06-16 | XNCR | Notice (144) | −2,215 | -$20.4K | EDGAR |
| 2025-06-16 | XNCR | Mixed | +11,471 | -$20.4K | EDGAR |
| 2024-12-04 | XNCR | Notice (144) | −1,421 | -$38.4K | EDGAR |
| 2024-12-04 | XNCR | Mixed | — | -$146.7K | EDGAR |
| 2024-12-02 | XNCR | Notice (144) | −13,301 | -$359.5K | EDGAR |
| 2024-10-01 | XNCR | Sell (S) | −1,853 | -$38.3K | EDGAR |
| 2024-09-27 | XNCR | Notice (144) | −1,853 | -$38.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.